LSLulu Si

Lulu Si

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lulu Si has a total of 15 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Natural Killer Cells in Uterine Adenomyosis: Immunological Mechanisms and Therapeutic Perspectives

    by Dilimulati Yalikun, Lulu Si, Hanlin Fu, Ruixia Guo

    Uterine adenomyosis (AM), a common gynecological disorder, is characterized by the invasion of endometrial glands and stroma into the myometrium, resulting in chronic pelvic inflammation and severe pain. This condition not only adversely affects patients’ quality of life but also correlates with diminished fertility. Recent findings underscore the critical role of natural killer (NK) cells in the pathophysiology of AM. As a vital component of innate immunity, NK cells are responsible for identifying and eliminating abnormal cells, and functional alterations of NK cells may contribute to the progression of this disease. Although existing research has suggested preliminary associations between NK‐cell dysfunction and AM, the exact mechanistic pathways and their clinical implications are still not fully elucidated. This review comprehensively explores the involvement of NK cells in AM, emphasizing their functional adaptability within the immune microenvironment, interactions with cytokine networks, and potential for therapeutic targeting. Furthermore, we critically assess the translational hurdles and propose a strategic framework for implementing NK cell‐based immunomodulatory approaches in clinical practice.

  • Open Access

    Molecular classification and fertility-sparing outcomes in endometrial cancer and atypical endometrial hyperplasia

    by Jiayi Wang, Guozhong Jiang, Shuping Yan, Yanpeng Tian, Yuxi Jin, Hanlin Fu, Lulu Si, Mingbo Cai, Xueyan Liu, Ruixia Guo

    Molecular classification has emerged as a critical tool for guiding personalized treatment in endometrial cancer (EC) and atypical endometrial hyperplasia (AEH). This retrospective study aimed to assess the impact of molecular classification on fertility-sparing treatment outcomes in patients diagnosed with EC and AEH who underwent fertility preservation therapy between 2006 and 2021. Patients were categorized into four molecular subtypes using immunohistochemistry (IHC) and Sanger sequencing, based on the Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE): POLE-ultramutated, mismatch repair (MMR) deficient (MMRd), p53 abnormal (p53abn), and p53 wild-type (p53wt). All patients were evaluated for oncological prognosis and fertility outcomes, with a total of 103 patients included in the analysis. Recurrence rates exhibited significant differences among the molecular classifications, with the lowest recurrence rate observed in the p53wt subtype (19.7%), followed by MMRd (30.4%), POLE-ultramutated (66.7%), and p53abn (71.4%) subtypes. Multivariate Cox regression analysis indicated that the p53abn subtype was a significant risk factor for recurrence following conservation therapy when compared to the p53wt subtype. Additionally, there was a notable disparity in standard surgical treatment due to treatment failure, with operation rates of 7.5%, 19.2%, 66.7%, and 57.1% for the p53wt, MMRd, POLE-ultramutated, and p53abn subtypes, respectively. Regarding fertility outcomes, the p53wt group demonstrated the highest pregnancy rate after achieving a complete response compared to the other subtypes; however, no significant differences were observed in overall pregnancy outcomes. The ProMisE molecular classification holds significant prognostic value for patients with EC and AEH undergoing fertility-sparing treatment. Among the molecular subtypes, p53wt appears to be the most favorable for fertility-preserving interventions. This study provides essential insights into reproductive outcomes for this patient population.